Background: Although allergen specific immunotherapy has been used as the only curative treatment for allergic diseases, there have been few studies that observed the efficacy of immunotherapy in asthmatics. Objectives : We attempted to determine clinical parameters for predicting the remission of asthma after immunotherapy with house dust mite extracts. Methods: Fifty-six adult asthmatic patients undergoing immunotherapy with house dust mite extracts for more than 3 years were enrolled. They were classified into the remitted and unremitted group according to the results of following methacholine challenge test. Skin reactivity, immunologic findings, spirometry, and airway hyperreactivity were compared between the 2 groups. Results: Twenty-six subjects (46.4%) were in the remitted group and 30 subjects (53.6%) were in the unremitted group. Both onset age of asthma symptoms and starting age of immunotherapy were significantly lower in the remitted group (P<0.05, for each). Baseline FEV1 levels and degree of airway hyperreactivity were significantly better in the remitted group (P<0.01 and 0.05, respectively). Conclusion: Younger age, earlier immunotherapy as well as better lung function and airway hyperreactivity at baseline can be used to predict the remission of asthma in adults. Therefore, earlier allergen immunotherapy in younger age group might help achieve remission in adult allergic asthma.
원문 PDF 다운로드
원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다. 원문복사서비스 안내 바로 가기
DOI 인용 스타일